Inherent resistance of myeloblasts to vincristine (VCR) has been related to the activity of myeloperoxidase (MPO) which can degrade VCR in the presence of hydrogen peroxide (H 2 O 2 ). We investigated the relationship between VCR degradation and hypochlorous acid (HOCl) generation from the reaction of H 2 O 2 with chlorine (Cl) as catalyzed by MPO. A cell-free system, three human leukemia cell lines (CEM/CCRF, HL-60, U937) and 15 bone marrow samples from children with acute myeloid leukemia (AML) were studied. VCR cytotoxicity was evaluated by MTT assay and by quantitative measurement of apoptosis. In vitro levels of VCR in cell-free systems were measured by high performance liquid chromatography (HPLC), and intracellular HOCl levels by oxidation of 5-thio-2-nitrobenzoic acid with the accompanying decrease in the absorbency at 412 nm. VCR was degraded by increasing concentrations of HOCl in cell-free systems and this activity was inhibited by taurine, which is known to block HOCl activity. This finding was confirmed by the VCR cytotoxicity studies on cell lines. The HOCl-producing myeloblasts from patients were resistant to VCR. In five samples out of eight HOCl was also detected extracellularly. These results suggest that oxidation by HOCl may be the final step in VCR degradation catalyzed by MPO through its action on intracellular H 2 O 2 and Cl. Leukemia (2000) 14, 47-51.
Introduction
Acute myeloid leukemia (AML) blasts are often found to be inherently resistant to vincristine (VCR), a cell cycle-specific alkaloid which induces metaphase arrest, and an effective drug in the treatment of acute lymphoblastic leukemia (ALL). 1, 2 Multi-drug resistance (MDR) function is one of the factors known to be associated with the development of VCR resistance. MDR function interferes with intracellular drug accumulation mediated by different effector proteins such as P-glycoprotein (P-gp), MDR-related protein (MRP) and lung resistance protein (LRP). Distinct membrane proteins from Pgp were found to cause decreased intracellular VCR accumulation 3 and MRP overexpression appears to be an additional factor in VCR resistance. 4, 5 While MDR expression is relatively common in adult AML, the true incidence of MDR expression in childhood AML is still to be determined. Thus at present, it would be difficult to explain the almost universal VCR resistance seen in AML by this mechanism.
It has also been hypothesized that VCR resistance in AML blasts is related to the presence of the lysosomal enzyme, myeloperoxidase (MPO, EC 1.11.1.7). VCR degradation activity of MPO depends on the intracellular presence of hydrogen peroxide (H 2 O 2 ).
1,2,6 MPO-mediated degradation of VCR in the presence of H 2 O 2 has been demonstrated in cellfree systems and leukemia cell lines. 1 This degradation correlated with cellular MPO activity and specific MPO inhibitors blocked VCR degradation. Moreover, MPO anti-sense RNA reduced MPO activity and increased VCR sensitivity. 7 Hence, MPO activity can be causally related to the loss of intracellular VCR activity. It is also known that MPO catalyzes the formation of hypochlorous acid (HOCl) from H 2 O 2 and chlorine (Cl). 8 We therefore hypothesized that HOCl, produced through the reaction of MPO, H 2 O 2 and intracellular Cl ion is the actual species involved in the oxidative degradation of VCR both in cell-free systems and human AML blasts.
Materials and methods

Patients
Fifteen patients with newly diagnosed AML were included in the study. Bone marrow samples were sent to the Pediatric Oncology Group (POG) MDR Reference Laboratory at Children's Hospital of Michigan for the POG 9421 Study from various POG institutions after informed consent was obtained. All studies were carried out in 12 of the samples and only HOCl measurements were done in the other three samples.
Chemicals
Vincristine sulphate and MPO (190-220 U/mg protein) were purchased from Fluka Chemical Corp (Milwaukee, WI, USA), H 2 O 2 (30%) and sodium hypochlorite (5%) from Fisher Scientific (Pittsburgh, PA, USA), sodium acetate, absolute isopropanol, (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 5,5Ј-dithiobis (2-nitrobenzoic acid) (DNTB), sodium borohydride, EDTA, NaCl, human erythrocyte catalase (EC 1.11.1.6) (30 000 U/mg), and taurine from Sigma Chemical Company (St Louis, MO, USA), potassium dihydrogen phosphate from Mallinckrodt (Paris, KY, USA), acetonitrile from Burdick and Jackson Company (Muskegon, MI, USA), cyclosporin A (CsA) (Sigma), rhodamine-123 (R123) (Molecular Probes, Eugene, OR, USA), dimethyl formamide (DMF) (Sigma).
Cell culture
Human cell lines and Ficoll-separated bone marrow mononuclear cells (BMMC) from children with AML were cultured in RPMI 1640 media supplemented with 2 mM L-glutamine (JRH Biosciences, Lenexa, KS, USA), 50 g/ml gentamycin, 1 × insulin-transferrin-selenite supplement (Sigma) and 15% heat inactivated dialyzed fetal bovine serum (FBS) (HyClone, Logan, UT, USA). Cultures were maintained in a humidified incubator at 37°C with 95% room air and 5% CO 2 . HL-60, CEM/CCRF, and U937 cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). Patient bone marrow cells were further supplemented with 20% supernatant from the human bladder carcinoma 5637. 9 This final solution will be termed as the complete RPMl 1640 media.
Flow cytometry
Flow cytometric analysis of intracellular MPO (iMPO) (Caltag Laboratories, Burlingame, CA, USA), cell surface antigen expression including multidrug resistance-associated p-glycoprotein (mdr-1) using MRK 16 monoclonal antibody (Kamiya, Thousand Oaks, CA, USA) were carried out as described previously. 10, 11 Cell surface marker expression was evaluated by using a panel of murine monoclonal antibodies including CD11b, CD33, CD34, CD13, CD14 and CD15 (Becton Dickinson, Mountain View, CA, USA). Analysis was performed using a Coulter XL Flow Cytometer (Coulter Corporation, Miami, FL, USA).
Cyclosporin A-mediated functional drug efflux assay using rhodamine-123
Cell suspensions at 5 × 10 5 cells/ml in RPMI 1640 + 10% FBS were aliquoted to 12 × 75 tubes (0.9 ml/tube) and pre-incubated at 37°C/5% CO 2 for 30 min with or without the addition of 10 M CsA. At the end of incubation, 100 l R123 was added to each tube at a final concentration of 0.3 M, except for the autofluorescence tube, and all tubes were incubated for an additional 30 min. The tubes were centrifuged, supernatant was discarded and cells were resuspended in corresponding R123-free medium and incubated an additional 30 min. Tubes were placed on ice and analyzed within 15 min for R123 uptake on FL3 by flow cytometer. Ratios of median channel fluorescence of R123 + CsA vs R123 alone gave measures of relative MDR efflux. R123 stock solutions (1 mM) were prepared in DMF and stored at −20°C and diluted to 3 M in PBS prior to assay. CsA stock solution was 2 mM prepared in absolute ethanol stored at −20°C.
In vitro oxidative degradation of vincristine
Incubations containing combinations of varying concentrations of H 2 O 2 , MPO, VCR, HOCl and taurine were performed in 15 ml plastic Falcon tubes in 5 ml of acetate buffer that included NaCl (2.5 mol/l at pH 6). Mixtures were incubated in the dark at 37°C for 3 h. Reaction was halted by placing the samples on ice and aliquots were stored at −70°C until analysis. Vincristine was assayed by a slight modification of the technique of Tassin et al, 12 both at the beginning and end of the incubation period. The high pressure liquid chromatographic (HPLC) system consisted of a Varian 9050 UV/visible detector, a 9012 ternary gradient pump (Varian Associates, Sugar Land, TX, USA), a Rheodyne 7125 injector equipped with a 100 l loop, and the Varian LC Star Workstation computerized software package for analysis. A reverse phase C-18 Hibar LiChrocart column (5 m, 250 × 4.0 mm) with an equivalent precolumn (Merck, Darmstadt, Germany) were utilized for all assays. Mobile phase consisted of 66.5% 0.2 M potassium dihydrogen phosphate buffer (pH 3.0) and 33.5% HPLC grade acetonitrile as organic modifier. Absorbance was set at 237 nm and flow rate at 0.8 ml/min at ambient temperature. Adjustment of the organic modifier percentage and flow rate were required because of the smaller particle size of the analytical column (7 in the original method vs 5 in ours) which caused reductions in retention time that coincided with the solvent front. Samples containing VCR (Table 1) were diluted with HPLC grade water and 25 l was injected. Samples containing MPO were first ultrafiltered through an Amicon centrifree microfilter (30 000 MW cutoff) in a fixed angle rotor refrigerated centrifuge for 15 min at 3500 r.p.m. (4°C). Filtrate was diluted with HPLC grade water and 25 l was injected. Standards (10-0.5 M) were made in duplicate with pure analytical grade VCR, linear regression curves calculated, and unknowns determined from these curves. Standards were run daily with their corresponding unknowns. All samples were kept on ice until injection, and all values are in M. Volumetric equivalents of various mixtures corresponding to 0.4 M VCR in 1 ml final volume from the VCR-alone incubation solution (as a negative control) were used in the experiments.
Cytotoxicity assays MTT assay:
The MTT assay was performed with VCR over a four log range (0.5-2000 nm) in microculture plates containing 20 l drug and 80 l cell suspensions in complete RPMI 1640 media. Final cell density was 1 × 10 6 cells/ml. Blanks consisted of only complete media, and cell viability was determined in wells devoid of the drug. Plates were incubated in a humidified incubator with 5% CO 2 for 2 days for cell lines and 3 days for patient samples at 37°C. At the end of incubation 10 l of MTT solution (5 mg/ml) was added and incubated an additional 6 h. Resulting formazan crystals were dissolved with 100 l of 0.04 N HCl in isopropanol. The optical density (OD) was measured with a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 595 nm. Cell survival was calculated by the following equation: percent cell survival = (OD treated well/mean OD control wells) × 100%
The LC 50 , defined as the drug concentration that results in Table 1 Oxidative degradation of VCR in a cell-free system 50% lethality, was derived by calculating the point at which the dose-response curve crosses the 50% survival point. Cell viability was tested by trypan blue exclusion.
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Apoptosis assay: Approximately 1 × 10 6 cells from either cell lines or patient bone marrow samples were incubated in 1 ml of complete RPMI 1640 with 15% FBS media for 16 h with or without VCR at 0.4 M (post-incubation solution of the cell-free system was used as the source) and volumetric equivalents of other combinations, such as VCR + H 2 O 2 or VCR + MPO, etc. Quantitative flow cytometric measurement of spontaneous and drug-induced apoptosis was performed by using the annexin V-propidium iodide (Ann V-PI) colabeling technique as described previously.
14 The annexin V-propidium iodide apoptosis kit was utilized for the assays (R&D Systems, Minneapolis, MN, USA). At the end of the incubation period cells were washed with phosphate-buffered saline (PBS), stained with Ann V-PI and incubated at room temperature for 20 min in the dark, and analyzed by flow cytometry. Ann V negative (−)/PI(−) fraction represented viable cells, Ann V positive (+)/PI(−) fraction early apoptotic cells, and Ann V(+)/PI(+) fraction late apoptotic and dead cells.
Flow cytometric analysis was based on the gated population by side and forward scatter characteristics of control samples. An apoptosis ratio was calculated according to the following formula: apoptosis index (%) = (viable cell percent in the control sample − viable cell percent in drug-treated sample)/viable cell percent in the control sample.
HOCl determination Cellular extraction:
BMMC from AML patients were suspended in 1 ml of Dulbecco's PBS with 0.4 M VCR in 24-well culture plates at 1 × 10 6 cells/well and incubated at 37°C for 2 h. After incubation, the suspensions were transferred to 1.5 ml Eppendorf tubes, centrifuged at 1500 r.p.m. for 5 min and supernatant removed. The pellet was resuspended in PBS and microfuged at 20 000 g for 2 min at 4°C. Supernate was separated and later used for HOCL determination. 150 l of distilled sterile water was added to the pellet, solution was vortexed and centrifuged for 5 min at 1500 r.p.m. The final supernate was removed and used for HOCl determination.
HOCl assay:
HOCL was determined by the method of Aune and Thomas 15 as later modified by Ching et al. 16 Standards were prepared by adding known amounts of NaOCl to water. Standards were prepared and incubated at 37°C for 5 min.
To 1 ml final volume was added 150 l of cell extract and 5-thio-2-nitrobenzoic acid (TNB) (made by adding 4.4 ml of 40 mM sodium borohydride to 1 mM DNTB in 50 mM phosphate buffer at pH 6.6 with 5 mM EDTA and incubating at 37°C for 30 min) sufficient to give a final concentration of 10 M. The sample was mixed, placed into a microplate and the absorbance followed for 2-3 min at 412 nm in a plate reader. HOCl was determined by comparing the change in absorbance of the unknown to that of known standards. Catalase (3 g/tube) was added prior to the addition of TNB to remove trace amounts of H 2 O 2 which could oxidize TNB.
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Results
The oxidation of VCR by HOCl was examined in cell-free systems in the presence of increasing concentrations of HOCl and showed complete loss of the parent molecule at a threshold concentration of 12.94 M (Figure 1 ). When examined as the percent of VCR remaining (using the equivalent amount of incubated sample of VCR without HOCl present as the 100% baseline) vs increasing HOCl concentration, at 20 M the parent VCR was totally lost from solution. During these experiments only 5-6% VCR was lost from controls (VCRalone sample) during the incubation period. The IC 50 concentration, at which 50% VCR remains, was calculated to be 2.82 M (Figure 1) .
VCR was degraded by HOCl, produced through the reaction of MPO and H 2 O 2 and the degradation was prevented by taurine ( The findings above were also supported by the cytotoxicity studies carried out on cell lines. When CEM cells were incubated with VCR and varying concentrations of HOCl, obtained from cell-free incubations (when volumetric equivalents of 0.4 M VCR-alone incubation samples were used), VCR cytotoxicity was inhibited by HOCl concentrations greater than 6.25 M (Figure 2 ). As expected, addition of taurine protected VCR from degradation, resulting in decreased cell viability. Similar results were obtained with all three cell lines by measuring apoptosis induced by the incubation products of various combinations of VCR, H 2 O 2 MPO, HOCL and taurine in cell-free systems (volumetric equivalents of 0.4 M VCR obtained from VCR-alone incubation sample). As seen in Figure 3 , incubation of VCR with H 2 O 2 or MPO did not affect cytotoxicity whereas, incubation with MPO and H 2 O 2 or HOCl decreased cytotoxicity significantly. The inhibition was more pronounced when VCR was incubated with HOCl. Again, taurine reversed the effect of MPO and H 2 O 2 or HOCl on VCR cytotoxicity as reflected by the normalization of cytotoxicity to the levels seen in incubation with VCR alone. HL- 60 cell line was found to be iMPO-positive whereas CEM/CCRF and U937 cells were iMPO negative. Consistently, CEM and U937 cell lines did not produce HOCl, but HL-60 produced 1.03 M HOCl.
AML samples revealed positive staining for a combination of myeloid antigens, including CD13 and CD33. Although MRK 16 expression was not increased significantly in any of the patient samples, post-incubation rhodamine 123 efflux ratio was high in two patients (patients 10 and 12) showing significant inhibition of operational MDR function by cyclosporin A (Table 2) . Of the 12 pediatric samples, 10 were iMPO positive. Intracellular HOCl production was demonstrated (2.4-15.6 M) in eight patients out of 15 and negative in the other seven. HOCl was also shown in the supernatant of VCRtreated AML cells in five patients out of eight HOCl-producing 
Discussion
VCR is an active compound in the treatment of ALL, whereas it is not efficient in eliminating myeloblasts from patients with AML. 6 Schlaifer et al 1 proposed a new VCR resistance mechanism in AML blasts. They demonstrated that MPO is capable of mediating oxidation of VCR in the presence of H 2 O 2 in both cell-free systems and in the MPO-positive human leukemia cell line, HL-60. 1, 7 It was reported that sera from patients with AML had increased ability to breakdown VCR and VCR degradation was further increased by adding H 2 O 2 .
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HOCl is produced in mature myeloid cells, such as neutrophils and has an important role in bacterial neutralization. 8 Our results indicate that there is a strong relationship between HOCl and VCR degradation. In cell-free systems, VCR was inactivate by HOCl and taurine inhibited this degradation. More interestingly, taurine also prevented VCR degradation significantly in the samples exposed to both MPO and H 2 O 2 . Since taurine is known to antagonize HOCl but not MPO activity, these findings clearly suggest that HOCl, produced as a result of MPO-H 2 O 2 interaction, inactivated VCR. 17 These results were supported by the studies on cell lines. When volumetric equivalents of 0.4 M VCR in 1 ml final volume from the VCR-alone incubation solution were used, VCR cytotoxicity was shown to be inhibited by HOCl or MPO + H 2 O 2 , and this inhibition was prevented by adding taurine.
Higher VCR LC 50 levels obtained in 11 patients out of 12, was consistent with the resistance pattern seen in AML. In all five patients with HOCl production, VCR LC 50 values were high, supporting a possible role played by HOCl in VCR degradation. However, in six patients with high VCR LC 50 values, we were not able to show HOCl production in our experimental setting. Two of these patients (patients 6 and 7) also did not have intracellular MPO expression as shown by negative staining with iMPO monoclonal antibody. In neither case were blast cells positive for MRK 16 or showed high efflux rates suggesting other operational mechanisms. One of the possible explanations for the absence of HOCl detection in the remaining four samples could be a low intracellular MPO activity despite the presence of detectable antigenic material. This assumption is somewhat supported by the low LC 50 value observed in a sample (patient 3) with positive iMPO staining which did not produce HOCl.
Although MDR function was found to be associated with VCR resistance, P-gp expression did not correlate with slow response to VCR-containing therapy regimens in childhood ALL. 18 In our study, blast cells from two patients with high VCR LC 50 and increased MDR function also had HOCl production indicating the presence of multiple factors contributing to VCR resistance in AML blasts. Moreover, VCR-induced apoptosis indexes observed in MPO-negative cell lines were quite close to HL-60, even lower, suggesting the involvement of different mechanisms in VCR resistance.
It has been shown that zymosan-stimulated peripheral neutrophils are capable of producing HOCl. 19 Theoretically, peripheral blood neutrophils may contribute to VCR degradation in the plasma by releasing HOCl, which in that case, may 2 Demonstration of HOCl in the supernatant of VCR-treated AML cells in five cases supports this opinion. Since it is a short incubation with VCR, it is unlikely that extracellular HOCl resulted from cellular death and disintegration. Detection of higher levels of HOCl in cellular extracts and absence of extracellular HOCl in three HOCl-producing cases further provide evidence for the intracellular production and secretion in some cases. In conclusion, our findings suggest that degradation of VCR is directly mediated by HOCl, produced during a reaction catalyzed by MPO and HCOl production is associated with VCR resistance in AML.
